<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to selecting initial systemic therapy in patients with extracranial metastatic cutaneous melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to selecting initial systemic therapy in patients with extracranial metastatic cutaneous melanoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to selecting initial systemic therapy in patients with extracranial metastatic cutaneous melanoma</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm summarizes our suggested approach to selecting initial systemic therapy in patients with extracranial metastatic cutaneous melanoma. The choice is based upon tumor <em>BRAF</em> mutation status, clinical features suggestive of aggressive disease, and the patient's performance status, comorbidities, and preferences. Prior to initiation of systemic therapy, tumors should be assessed for actionable mutations such as <em>BRAF</em>. The treatments listed in this figure are our preferred options; however, alternative agents that are not listed may also be effective. Enrollment in a clinical trial is encouraged if available. For patients with brain (eg, intracranial) metastases, additional considerations factor into choice of therapy. For additional details, refer to UpToDate content on systemic treatment of metastatic melanoma with molecular alterations and management of brain metastases in melanoma.</div><div class="graphic_footnotes"><p>LDH: lactate dehydrogenase; AJCC: American Joint Committee on Cancer; PFS: progression-free survival.</p>
<p>* Eligibility for immunotherapy is influenced by patient performance status, medical comorbidities, history of autoimmune disease, and use of immunosuppressive therapy, including glucocorticoids. Refer to UpToDate content on systemic treatment of metastatic melanoma with molecular alterations.</p>
<p>¶ The presence of brain (ie, intracranial) metastases also signals aggressive disease. However, management of patients with brain metastases is complex and may also involve other treatment strategies. Refer to UpToDate content on management of brain metastases in melanoma.</p>
<p>Δ In patients with <em>BRAF</em> V600 mutant melanoma, we recommend combination immunotherapy with nivolumab plus ipilimumab over combination targeted therapy with BRAF plus MEK inhibitors as this approach improves overall survival and offers a greater opportunity for long-term treatment-free survival. For those unlikely to tolerate nivolumab plus ipilimumab (eg, older adults, patients with a history of autoimmune disease), the combination of nivolumab-relatlimab is an appropriate alternative and is preferred over single-agent immunotherapy.</p>
<p>◊ Single-agent immunotherapy is an option for patients who are anticipated to not tolerate the potential toxicities of combination immunotherapy. In patients with pre-existing autoimmune disease, limited data suggest that most can safely receive checkpoint inhibitor immunotherapy, but may be at higher risk for specific irAEs or exacerbation of their underlying autoimmune disorders. Refer to UpToDate content on toxicities associated with immunotherapy.</p>
<p>§ All combinations are reasonable options. While not compared directly, all appear to have similar efficacy. Selection is based on sites of metastatic disease, patient convenience, and potential toxicities. Refer to UpToDate content on systemic treatment of metastatic melanoma with molecular alterations.</p>
¥ Nivolumab-relatlimab is an option for patients with <em>BRAF</em> wild-type tumors and features of aggressive disease who are anticipated to not tolerate the potential toxicities of nivolumab plus ipilimumab. Nivolumab-relatlimab improved PFS in a randomized trial and has a more favorable toxicity profile than nivolumab plus ipilimumab.</div><div id="graphicVersion">Graphic 105384 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
